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241.doi:10.1016/j.jtcvs.2005.02.005Background: Although radioisotopic procedures are commonly used to detect sen-
tinel lymph nodes in breast cancer surgery, these procedures are often problematic
and not necessarily suitable for lung cancer surgery.
Methods: Our previous study revealed that the mediastinal sentinel lymph node,
defined as the regional mediastinal lymph node, consisted of nodes 2, 3, or 4 in right
upper lobe cancers; 3, 7, or 8 in right lower lobe cancers; 4, 5, or 7 in left upper lobe
cancers; and 4, 7, or 8 in left lower lobe cancers. On the basis of these findings, we
pathologically investigated one representative lymph node at each of the 3 levels
dissected during surgical intervention in 69 patients with non–small cell lung cancer
from September 1993 through December 2002. Fifty-eight patients with lung cancer
underwent lobectomies with limited mediastinal lymph node dissection according to
this strategy.
Results: Mediastinal lymph node recurrence was observed in only one patient during
41  25 months (maximum, 98 months) of follow-up. The cancer-specific 5-year
survivals were 96.6% in patients with pathologic stage IA disease (n  31) and
67.4% in patients with stage IB disease (n  16).
Conclusion: These results suggested that limited mediastinal lymph node dissection
is applicable to patients with non–small cell lung cancer whose regional mediastinal
lymph nodes are not metastatic.
Sentinel lymph node mapping techniques have been extensively studied inmelanoma and breast cancers,1-3 and they are now applied to most solidtumors. Usually these techniques involve the preoperative injection of a blue
dye or radioisotope into the peritumoral tissue, which allows the sentinel lymph
nodes to be detected during surgical intervention. However, there are some diffi-
culties with these methods in their application to lung cancer surgery. First,
preoperative computed tomography–guided injections of a radioisotope or blue dye
into the lung are somewhat troublesome; second, blue dye is not so beneficial for
anthracotic lymph nodes.
We4 previously investigated which mediastinal lymph node levels should be
examined during surgical intervention to diagnose N2 or less than N2 disease in
patients with bronchogenic carcinomas. With primary tumors, 3 mediastinal lymph
node levels were selected for each lobe and defined as regional mediastinal lymph
nodes; the idea of the regional mediastinal lymph node is quite similar to that of the
sentinel lymph node. However, investigation of the regional mediastinal lymph node
is more practical and convenient than sentinel lymph node examination by means of
tracer-guided sentinel lymph node biopsy techniques because regional mediastinal
lymph nodes are examined pathologically during surgical intervention without any
special equipment. We suggested that if the regional mediastinal lymph nodes are
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be stopped at this point without the additional mediastinal
lymph node dissection.
Thus, a prospective study of limited mediastinal lymph
node dissection on the basis of the idea of the regional
mediastinal lymph node was commenced in 1993. This
report shows the follow-up results of this study and dis-
cusses the validity of the proposed method.
Patients and Methods
As a preliminary study,4 we retrospectively reviewed the patterns
of mediastinal lymph node metastasis in relation to the location of
primary lung cancer in 55 patients with pathologic N2 disease who
underwent resection of a primary lesion and standard mediastinal
lymphadenectomy. Lymph node mapping was conducted accord-
ing to the criteria of the Japanese Lung Cancer Society.5 Medias-
tinal lymph node metastasis was detected in 100% (17/17) of
patients with right upper lobe cancers by examination of node
levels 2, 3, and 4; in 91% (20/22) by examination of node levels 3,
7, and 8 in right lower lobe cancers; in 91% (10/11) by examina-
tion of node levels 4, 5, and 7 in left upper lobe cancers; and in
TABLE 1. Lymph node levels for regional and standard
mediastinal node dissection
Tumor location
Regional node
dissection
Standard node
dissection
Right upper lobe 2, 3, 4 1, 2, 3, 4, 7
Right lower lobe 3, 7, 8 1, 2, 3, 4, 7, 8, 9
Left upper lobe 4, 5, 7 4, 5, 6, 7
Left lower lobe 4, 7, 8 4, 5, 6, 7, 8, 9
TABLE 2. Patient characteristics
Mean age (y) 68 8 (44-83)
Sex
Male 45
Female 13
Primary site
RUL 24
RLL 10
LUL 13
LLL 11
Histology
Adenocarcinoma 24
Squamous cell carcinoma 29
Large cell carcinoma 2
Carcinoid 2
Unknown 1
Surgical intervention
Lobectomy 58
Pneumonectomy 1
RUL, Right upper lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left
lower lobe.100% (5/5) by examination of node levels 4, 7, and 8 in left lower
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because of the small number. As a prospective study, these 3 levels
were investigated pathologically during surgical intervention by
examining one representative lymph node most strongly suspected
to be metastatic, which means the largest node, nonanthracotic
node, or both in each of the 3 levels dissected in 61 patients. The
N status diagnosed according to the frozen sections (f-N) during
surgical intervention was compared with the N status diagnosed
according to the permanent sections (p-N) obtained after the stan-
dard mediastinal dissections. The f-N value was consistent with the
p-N value in 39 patients with N0 or N1 disease and in 16 patients
with N2 disease or more. Thus, 90% of the f-N values were consis-
tent with the p-N values. The f-N values resulted in underdiagnosis in
6 patients, 4 of whom had a micrometastasis in only one of the lymph
nodes dissected from the 3 levels. Because the 3 levels were com-
pletely dissected, there were no residual metastatic lymph nodes. The
remaining 2 patients had metastatic lymph nodes outside the 3 levels.
Standard mediastinal lymph node dissection was performed for these
2 patients because the lymph node was macroscopically suspected to
be metastatic; this was pathologically confirmed by means of frozen
sectioning during surgical intervention. The 3 levels for each lobe are
shown in Table 1.
The present study was conducted on the basis of the results of
the preliminary study. From September 1993 through December
2002, 308 patients underwent surgical intervention for primary
lung cancer in our institute. Patients with preoperative mediasti-
noscopy, patients with N2 disease proved by video-assisted tho-
racic surgery, and those who had undergone partial resections or
segmentectomies were excluded. Sixty-nine patients from whom
informed consent for limited mediastinal lymph node dissection
was obtained were included in this study. A total of 3 lymph nodes
TABLE 3. Postoperative staging and LN status
Pathologic stage
IA 31
IB 16
IIA 1
IIB 7
IIIA 2
IIIB 1
IV 0
LN status
N0 52
N1 5
N2 1
N3 0
LN, Lymph node.
TABLE 4. Recurrence
Distant metastasis 7
Local recurrence 2
Bronchial stump 1
Mediastinal LN 1
LN, Lymph node.(one representative mediastinal lymph node in each level) were
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pleting dissections of the hilar lymph nodes and regional medias-
tinal lymph nodes. If the frozen sections did not show lymph node
metastasis, no further lymph node dissection was performed. If the
frozen sections revealed lymph node metastasis, standard medias-
tinal lymph node dissection was conducted. All of the dissected
lymph nodes, including the frozen sections, were examined by
Figure 1. Cancer-specific and overall survivals of the 5
dissection.Figure 2. Cancer-specific and overall survivals
The Journal of Thoracimeans of permanent sectioning. The lymph node levels of the
limited (regional) and standard mediastinal node dissections are
shown in Table 1.
The patients were followed up every month within the first 6
months after surgical intervention at an outpatient clinic and every
2 months thereafter. During the follow-up period, plain chest x-ray
films and serum tumor marker levels were obtained. Brain, chest,
tients who underwent limited mediastinal lymph node8 paof the 31 patients with stage Ia disease.
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scintigraphies, were performed every 6 months to detect tumor
recurrence. The mean follow-up time of the patients was 41  25
months (range, 2-98 months).
All values are given as the mean  standard deviation. The
Kaplan-Meier method was used to evaluate patient prognosis.
Results
Of the 69 cases studied, 11 were positive for regional
mediastinal lymph nodes, and these patients underwent
standard mediastinal lymph node dissections. Fifty-eight
were negative for regional mediastinal lymph nodes, and
these patients did not undergo additional mediastinal lymph
node dissection. The characteristics of the 58 patients are
shown in Table 2.
Table 3 shows the pathologic staging and lymph node
status of the 58 patients studied. Most patients were classi-
fied as having stage Ia or Ib disease. Postoperative staging
revealed 1 false-negative case; micrometastasis was not
detected in the frozen section from this patient. During the
follow-up period, there were 9 recurrent cases, including 7
distant and 2 local recurrences (Table 4). Only one medi-
astinal lymph node recurrence was observed outside of the
3 levels.
The Kaplan-Meier survival curves of the 58 patients are
shown in Figure 1. The cancer-specific 5-year and overall
5-year survivals were 82.0% and 69.2%, respectively. The
survival curves of the patients with stage Ia disease (n 31)
are shown in Figure 2; their cancer-specific and overall
Figure 3. Cancer-specific and overall surv5-year survivals were 96.6% and 83.9%, respectively. The
436 The Journal of Thoracic and Cardiovascular Surgery ● Augusurvival curves of the patients with stage Ib disease (n 16)
are shown in Figure 3; their cancer-specific and overall
5-year survivals were 67.4% and 51.7%, respectively. Good
prognoses were observed, equal to those of the latest major
report in Japan on 7508 patients with lung cancer.6
Discussion
Lymph node metastasis is the most important prognostic
factor of localized non–small cell lung cancer (NSCLC).7-9
Accurate detection of lymph node metastasis therefore
yields accurate predictions of patient prognosis. Lobectomy
and standard mediastinal node dissection are common sur-
gical procedures for localized NSCLCs in Japan.5 Hilar and
mediastinal node dissections might improve survival in
patients with stage II and IIIa NSCLC10; however, it cannot
be suggested that lymph node dissection improves the prog-
nosis of patients without lymph node metastasis. To diag-
nose N1 or lower diseases, mediastinal lymph nodes must
be investigated because skip metastasis to mediastinal
lymph nodes is often observed.11
Sentinel lymph node–mapping procedures have already
been applied to most solid malignant tumors.1-3,12 In breast
cancers sentinel lymph node–mapping procedures are be-
coming the standard operative procedure. Liptay and asso-
ciates13 reported that radioisotope (RI)-guided sentinel
lymph node mapping techniques are applicable for lung
cancer surgery. It has also been reported that precise histo-
logic examinations of sentinel lymph nodes yield more
of the 16 patients with stage Ib disease.ivalsaccurate diagnoses of lymph node metastasis. Schmidt and
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lymph node mapping techniques in lung cancer. However,
the validity of sentinel lymph node mapping techniques for
limited mediastinal lymph node dissection has yet to be
determined.
The 3 determined levels in the mediastinal lymph nodes
(Table 1) were recognized as the regional mediastinal
lymph nodes for each lobe. The 3 levels are extremely
consistent with the anatomic lymphatic efferent pathways
from each lung.15,16 The patterns of mediastinal lymph node
metastasis reported in other reports are relatively similar to
our results,11,16,17 and therefore the idea of determining and
examining 3 levels of mediastinal lymph nodes during sur-
gical intervention is similar to the method of sentinel lymph
node mapping. However, our method seems more practical
and convenient in the clinical setting than sentinel lymph
node mapping, which requires special equipment.
Table 1 compares the settings of limited (regional) me-
diastinal lymph node dissection and standard lymph node
dissection. Limited (regional) mediastinal lymph node dis-
section is apparently less invasive compared with standard
lymph node dissection, except for the left upper lobe.
Residual mediastinal lymph node recurrence was expe-
rienced in one case with an adenocarcinoma in the left lower
lobe and partial involvement of the left upper lobe. The
patient underwent a left lower lobectomy and partial resec-
tion of the left upper lobe with limited (regional) mediasti-
nal dissection of lymph nodes 4, 7, and 8. Recurrence in
lymph nodes 1, 2, 3, and 5 was observed 13 months after
surgical intervention. It is likely that we failed to detect the
lymph node metastasis in level 5, which is the regional
lymph node of the left upper lobe. Therefore, our method
should not be applied to patients with extralobar
involvement.
Rare cases with extraregional skip metastasis have been
reported previously (ie, metastasis to the level 7 nodes in
upper lobe cancers). Anatomic investigation, including
lymph scintigraphy, revealed that direct lymphatic flow to
extraregional lymph nodes existed in some patients.11,15
Although there was no extraregional nodal recurrence in our
patients, we surmise that the small possibility of extra-
regional skip metastasis exists in the limited mediastinal
lymph node dissection.
The survivals of the patients who underwent limited
(regional) mediastinal lymph node dissection showed no
inferiority to those in the latest report in Japan on lung
cancer.6 There was no mediastinal lymph node recurrence in
the 57 patients whose indications were thought to be appro-
priate. These findings indicate the applicability and validity
The Journal of Thoraciof limited mediastinal lymph node dissection in selected
patients with NSCLC according to intraoperative histologic
examinations.
From 1999, a prospective randomized trial of nodal
sampling versus complete mediastinal nodal dissection was
conducted by the American College of Surgeons Oncology
Group (ACOSOG), and it was recently closed. This study
consisted of 1000 patients (one arm  500 patients). It is
expected that the follow-up results will confirm the validity
of the nodal sampling method.
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